This clinical trial is for adult participants who have triple-negative breast cancer (TNBC) without pathological complete response (pCR), as determined at the time of their surgery following neoadjuvant therapy. The term TNBC refers to the fact that the cancer cells do not have estrogen or progesterone receptors (ER or PR) and also do not make any or much of the protein called HER2 (human epidermal growth factor receptor 2). The term pCR refers to the absence of all signs of cancer in tissue removed during surgery.

This clinical trial is for men and women with newly diagnosed with acute Graft vs Host Disease (GvHD).

The purpose of this study is to evaluate if CYP-001 can be effective to treat GvHD that has not responded to steroids.

The study drug used in this study (CYP-001) is experimental. This means that it is not an approved treatment for high-risk acute GvHD by the U.S. Food and Drug Administration (FDA) or anywhere in the world.

Almost 10 million children in the United States are affected by at least one allergic disease and the rates of allergy are rising. Prior public health research shows that children born to individuals who are anxious during pregnancy have higher rates of allergy, but the cause behind this occurrence is not known.

This study is being done to look at the safety of delivering pulsed electric fields (PEF) to tumor(s) in patients with metastatic cancer within the lungs requiring biopsy, or tumor(s) from stage IV non-small cell lung cancer (NSCLC) requiring biopsy, who have not previously had treatment for the tumor(s), who are not surgical candidates, and who are considered eligible for first-line standard-of-care (SOC) cancer therapy. 
   

This study aims to learn more about the effects of naproxen and aspirin on the normal colon in people with Lynch syndrome. By doing this study, the study team hopes to gather information on the safety and effectiveness of naproxen and/or aspirin for the use of cancer immune interception in Lynch syndrome. Naproxen or aspirin may help to prevent the development of cancerous cells in the colon.   
  

This clinical trial is for adult participants who have advanced blood cancer that has been previously treated and is now unresponsive.
   
The purpose of this study is to learn more about the safety and effectiveness of using an investigational drug, NC525, in the treatment of blood cancer. An “Investigational” drug means it has not been approved for marketing by any health authority including the U.S. Food and Drug Administration (FDA).
   

This clinical trial is for adult participants who have a diagnosis of immune-mediated thrombotic thrombocytopenic purpura (iTTP).
   
The purpose of this study is to find out if an investigational study drug called TAK-755 is effective in treating iTTP with and without the current standard-of-care (SoC) treatment, which is daily plasma exchange (PEX). The purpose is also to find out how safe TAK-755 is, what are the side effects that might be related to it, and how often do they occur.
   

This clinical trial is designed for men and women with Essential thrombocythemia (ET) and either need to start with therapy to reduce their blood counts, or their current therapy is not sufficiently controlling their disease.
   
The purpose of this study is to evaluate if the study drug, P1101 (Ropeginterferon alfa-2b-njft) can normalize blood counts and the safety of P1101. 
   

This study is being done to identify if there is a safe, tolerable, and effective schedule of pomalidomide treatment when it is given in combination after induction therapy with daunorubicin and cytarabine liposome for acute myeloid leukemia (AML). Additionally, the study will evaluate if the combination of pomalidomide and daunorubicin and cytarabine liposome induction therapy is more effective in controlling AML than induction therapy with daunorubicin and cytarabine liposome alone.
   

This study is being done to evaluate if adding the drug ipatasertib to the usual approach is able to safely lower the chance of head and neck squamous cell cancer growing or spreading. This study aims to determine if this approach is better or worse than the usual approach.

The usual approach consists of treatment with immunotherapy using pembrolizumab. Pembrolizumab is approved by the U.S. Food and Drug Administration (FDA) and is administered through a vein in the arm.